WILMINGTON, MA--(Marketwired - Jun 13, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the Company will exhibit its QS-B220 explosives and drugs desktop trace detector and its QS-H150 handheld explosives trace detector at booth # 208 on June 16th through 18th in Greenville, South Carolina at the Adjutants General Association of the United States (AGAUS) annual conference.
AGAUS is made up of the 54 Adjutants General of the sovereign States, Territories, and the District of Columbia. Each Adjutant General is the senior military official in his or her State, Territory, or District. AGAUS is committed to a central leadership role in promoting and supporting adequate state and national security; and promoting the efficiency of the U.S. National Guard.
Conference attendees include Adjutants General or their designated representatives, National Guard senior leadership, and members of industry who support the National Guard. Conference topics will include: force structure and modernization; homeland defense and security; infrastructure, facilities and IT; strategic planning; and personnel.
"The U.S. National Guard plays a central role in our homeland security and we look forward to presenting our Quantum Sniffers™ as tools that can help them continue to deliver on their mission. Our trace detectors are currently being used by similar national security organizations in numerous countries around the world. We believe that following the recent TSA approval of our QS-B220, U.S. security forces will look to our equipment as a component of their multi-layered security approach," stated Implant Sciences' Vice President of Sales & Marketing, Dr. Darryl Jones.
Representing the 11th largest army in the world, the 5th largest Air Force, 38% of the total U.S. Military Force Structure, and more than 458,000 personnel serving in 3,600 communities throughout the country, the National Guard has provided America's Homeland Defense for over 375 years.
About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.